Literature DB >> 11684316

Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine.

Betsy Abraham1, Yaela Baine, Norbert De-Clercq, Etienne Tordeur, Pascal P Gerard, Patrick L Manouvriez, Dennis L Parenti.   

Abstract

Interference between antibodies generated by a combination hepatitis A and B vaccine was investigated by evaluating the quantity and quality of anti-hepatitis A virus (HAV) and anti-hepatitis B surface antigen (HBs) antibodies generated by Twinrix (Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine). The magnitude of the immune response was determined by a retrospective analysis of eight clinical trials, completed during stepwise development of Twinrix. The functionality of anti-HAV was evaluated by comparison of routine ELISA results with neutralization assays and was further characterized by defining the epitope-specificity of binding. Functionality of the anti-HBs response was not tested because a validated assay was not developed at the time this study was conducted. Results of all analyses demonstrated that the combination vaccine induced high antibody titers against hepatitis A and B and a functional anti-HAV response, with no evidence of immune interference to either viral antigen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11684316     DOI: 10.1016/s0166-3542(01)00194-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India.

Authors:  Zahid Hussain; Syed S Ali; Syed A Husain; Mohammad Raish; Deepika R Sharma; Premashis Kar
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Severe necrotizing pancreatitis following combined hepatitis A and B vaccination.

Authors:  Eran Shlomovitz; Ward Davies; Ewa Cairns; William C Brintnell; Mark Goldszmidt; George K Dresser
Journal:  CMAJ       Date:  2007-01-30       Impact factor: 8.262

3.  Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders.

Authors:  Kunal Das; R K Gupta; V Kumar; P Kar
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

4.  Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection.

Authors:  Srivamshi Pittala; Kenneth Bagley; Jennifer A Schwartz; Eric P Brown; Joshua A Weiner; Ilia J Prado; Wenlei Zhang; Rong Xu; Ayuko Ota-Setlik; Ranajit Pal; Xiaoying Shen; Charles Beck; Guido Ferrari; George K Lewis; Celia C LaBranche; David C Montefiori; Georgia D Tomaras; Galit Alter; Mario Roederer; Timothy R Fouts; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  Mol Syst Biol       Date:  2019-05-02       Impact factor: 11.429

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.